Cognivia-Mayo Collaboration Targets 3 Behavioral Drivers to Improve Trial Retention

For biopharma companies, the success of a multi-million-dollar clinical trial can hinge on something as mundane as a patient forgetting to take a pill or missing a follow-up visit. Cognivia's collaboration with Mayo Clinic aims to turn these erratic human factors into predictable data points—targeting non-adherence, missed appointments, and trial dropout with early detection tools that could slash costly delays and strengthen data integrity.

On June 23, 2026, Belgian behavioral intelligence company Cognivia announced a collaboration with Mayo Clinic, one of the world's most prestigious medical institutions, to bring behavioral intelligence to the forefront of clinical research and patient care. The partnership zeroes in on three pervasive and costly behavioral drivers of health outcomes: non-adherence to treatment plans, missed appointments, and clinical trial dropout. While biopharma and healthcare have long optimized biological and clinical variables, this collaboration signals a shift toward systematizing the human behavioral element—often the silent saboteur of even the best-designed interventions.

“

Clinical trial failure rates remain stubbornly high, with over 80% of studies failing to meet recruitment or retention targets, and patient non-adherence alone costing the healthcare ecosystem an estimated $300 billion annually in the United States.

The timing is significant. Clinical trial failure rates remain stubbornly high, with over 80% of studies failing to meet recruitment or retention targets, and patient non-adherence alone costing the healthcare ecosystem an estimated $300 billion annually in the United States. Sponsors routinely budget for dropout rates of 20–30% in late-stage trials, yet the underlying behavioral drivers are rarely measured or proactively managed. Cognivia claims its platform can make patient behavior "measurable and actionable," giving sponsors and care teams early visibility into individuals at risk of deviation. By integrating Mayo Clinic's expertise in shared decision-making and patient-centered care, the collaboration aims to translate predictive behavioral signals into timely, personalized interventions.

The initial focus on non-adherence, missed appointments, and dropout rates touches the entire value chain. In clinical research, every participant lost to follow-up increases statistical noise, extends timelines, and raises costs, often requiring over-enrollment to compensate. A tool that can flag a patient likely to miss visits or skip doses allows for preemptive engagement—transportation assistance, medication reminders, or extra counseling—that could materially improve trial power and reduce the number of unnecessary rescue dollars spent. For clinical care, the same intelligence helps health systems avoid the cascading consequences of missed visits: disease progression, emergency department overcrowding, and caregiver burnout.

Cognivia's Chief Executive Officer, Dominique Demolle, Ph.D., underscored that "for decades, healthcare has focused on biological and clinical factors while having limited ability to systematically measure and address patient behavior." This statement highlights the industry's historical blind spot. Advances in genomics, biomarkers, and digital endpoints have far outpaced our capacity to understand why patients do—or do not—follow through on a treatment plan. The collaboration promises to close that gap by embedding behavioral analytics into existing workflows, from electronic health records to electronic clinical outcome assessments.